Compare PZG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZG | TENX |
|---|---|---|
| Founded | 1992 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0M | 73.8M |
| IPO Year | 2015 | 2001 |
| Metric | PZG | TENX |
|---|---|---|
| Price | $0.94 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $10.29 |
| AVG Volume (30 Days) | 265.9K | ★ 1.4M |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,259.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $1.31 |
| 52 Week High | $2.70 | $19.40 |
| Indicator | PZG | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 34.99 |
| Support Level | $0.88 | $1.34 |
| Resistance Level | $1.06 | $2.01 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 37.86 | 4.46 |
Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold and Bald Peak Project.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.